Free fatty acids: Potential proinflammatory mediators in rheumatic diseases

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 303-310

  Frommer, Klaus W ^a   Schäffler, Andreas ^a   Rehart, Stefan ^b   Lehr, Angela ^b   Müller Ladner, Ulf ^a   Neumann, Elena ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; FATTY ACID DERIVATIVE; HEPTADECANOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LAURIC ACID; LINOLEIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; STEARIC ACID; STROMELYSIN; TOLL LIKE RECEPTOR 4; UNDECANOIC ACID; AUTACOID; CCL2 PROTEIN, HUMAN; FATTY ACID; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; MMP1 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

AGED; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; FATTY ACID TRANSPORT; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OSTEOARTHRITIS; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANTIGENS, CD36; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHEMOKINE CCL2; CHONDROCYTES; ENDOTHELIAL CELLS; FATTY ACIDS, NONESTERIFIED; FIBROBLASTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; OSTEOARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTOR 4;

EID: 84918536596     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203755     Document Type: Article

References (53)

1. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev 2007;29:1-5.
2. O'Rourke RW. Inflammation in obesity-related diseases. Surgery 2009;145:255-9.
3. Klein-Wieringa IR, Kloppenburg M, Bastiaansen-Jenniskens YM, et al. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann Rheum Dis 2011;70:851-7.
4. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
5. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008;37:635-46, viii-ix.
6. Kelley DE, Mokan M, Simoneau JA, et al. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993;92:91-8.
7. Rebrin K, Steil GM, Mittelman SD, et al. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest 1996;98:741-9.
8. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994;93:870-6.
9. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230-9.
10. Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000;49:1231-8.
11. Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 2003;111:246-50.
12. Schäffler A, Gross P, Buettner R, et al. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009;126:233-45.
13. Haversen L, Danielsson KN, Fogelstrand L, et al. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 2009;202:382-93.
14. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25.
15. Kopp A, Gross P, Falk W, et al. Fatty acids as metabolic mediators in innate immunity. Eur J Clin Invest 2009;39:924-33.
16. Ajeganova S, Andersson ML, Hafström I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken) 2013;65:78-87.
17. Coggon D, Reading I, Croft P, et al. Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord 2001;25:622-7.
18. Cooper C, Inskip H, Croft P, et al. Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity. Am J Epidemiol 1998;147:516-22.
19. Crowson CS, Matteson EL, Davis JM III, et al. Obesity fuels the upsurge in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012.
20. Felson DT, Chaisson CE. Understanding the relationship between body weight and osteoarthritis. Baillieres Clin Rheumatol 1997;11:671-81.
21. Jon Love T, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71:1273-7.
22. Karlson EW, Mandl LA, Aweh GN, et al. Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors. Am J Med 2003;114:93-8.
23. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012;71:1267-72.
24. Oliveria SA, Felson DT, Cirillo PA, et al. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 1999;10:161-6.
25. Holmberg S, Thelin A, Thelin N. Knee osteoarthritis and body mass index: a population-based case-control study. Scand J Rheumatol 2005;34:59-64.
26. Neumann E, Frommer KW, Vasile M, et al. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 2011;63:1159-69.
27. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233-55.
28. Del Rey MJ, Usategui A, Izquierdo E, et al. Transcriptome analysis reveals specific changes in osteoarthritis synovial fibroblasts. Ann Rheum Dis 2012;71:275-80.
29. Boyle DL, Kavanaugh A. The pathobiology of psoriatic synovium. Curr Opin Rheumatol 2008;20:404-7.
30. Otero M, Goldring MB. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res Ther 2007;9:220.
31. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008;10:224.
32. McCormack WJ, Parker AE, O'Neill LA. Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther 2009;11:243.
33. Lee JY, Zhao L, Youn HS, et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004;279:16971-9.
34. Wong SW, Kwon MJ, Choi AM, et al. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009;284:27384-92.
35. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
36. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
37. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
38. Neumann E, Judex M, Kullmann F, et al. Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther 2002;9:1508-19.
39. Neumann E, Kullmann F, Judex M, et al. Identification of differentially expressed genes in rheumatoid arthritis by a combination of complementary DNA array and RNA arbitrarily primed-polymerase chain reaction. Arthritis Rheum 2002;46:52-63.
40. Spector AA, Hoak JC. An improved method for the addition of long-chain free fatty acid to protein solutions. Anal Biochem 1969;32:297-302.
41. Coort SL, Willems J, Coumans WA, et al. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 2002;239:213-19.
42. Coats SR, Pham TT, Bainbridge BW, et al. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex. J Immunol 2005;175:4490-8.
43. Saitoh S, Akashi S, Yamada T, et al. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 2004;16:961-9.
44. Visintin A, Halmen KA, Latz E, et al. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005;175:6465-72.
45. Ii M, Matsunaga N, Hazeki K, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl) sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006;69:1288-95.
46. Kawamoto T, Ii M, Kitazaki T, et al. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 2008;584:40-8.
47. Holloway GP, Luiken JJ, Glatz JF, et al. Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. Acta Physiol (Oxf) 2008;194:293-309.
48. Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008;9:132.
49. Kalichman L, Kobyliansky E. Hand osteoarthritis in Chuvashian population: prevalence and determinants. Rheumatol Int 2009;30:85-92.
50. Griffin TM, Huebner JL, Kraus VB, et al. Induction of osteoarthritis and metabolic inflammation by a very high-fat diet in mice: effects of short-term exercise. Arthritis Rheum 2012;64:443-53.
51. Toda Y, Toda T, Takemura S, et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998;25:2181-6.
52. Gudbergsen H, Boesen M, Lohmander LS, et al. Weight loss is effective for symptomatic relief in obese subjects with knee osteoarthritis independently of joint damage severity assessed by high-field MRI and radiography. Osteoarthritis Cartilage 2012;20:495-502.
53. Ospelt C, Brentano F, Rengel Y, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008;58:3684-92.